All results

3 results for randomized controlled open label single ascending dose phase iii study investigate

• BOSTON 3

  The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and…

  Ages

  18 Years - N/A

  Sexes

  All

• u-STOP LVAD Bleed

  This is a Phase I, single ascending dose, first in human, open-label, non-controlled, dose-escalation trial that will investigate intravenous infusions of…

  Ages

  18 Years - 80 Years

  Sexes

  All

• Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST

  This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…

  Ages

  12 Years - 99 Years

  Sexes

  All